Bioresorbable scaffolds for natural breast reconstruction
Read MoreWHO WE ARE
Tensive is a clinical-stage medical device company developing the REGENERA™ / SOFTAG™ resorbable biopolymer scaffolds.
REGENERA™/SOFTAG™ for natural breast reconstruction and tissue marking following lumpectomy
Excellent safety profile — Encouraging secondary performance endpoints — High levels of patient and surgeon satisfaction
100
+100
+patients implanted
23
mln23
mlnraised
Check out our latest
- Alessandro Zeni
- 0 Comments
LSI Europe ’26 – Barcelona, September 28–October 1, 2026
Sanjay Kakkar, CEO of Tensive, has been selected to present at LSI Europe ’26 in Barcelona on the morning of […]
- Alessandro Zeni
- 0 Comments
Tensive reports pivotal 12-month clinical trial data confirming REGENERA™ delivers natural breast reconstruction after lumpectomy
Milan, Italy – July 28, 2026 – Tensive S.r.l., a clinical-stage advanced biomaterials medical device company, and the developer of […]
- Alessandro Zeni
- 0 Comments
Tensive appoints Peter Crosby Chairman as its bioresorbable breast reconstruction scaffold approaches regulatory approval
Milan, Italy – July 8, 2026 – Tensive S.r.l., a clinical-stage advanced biomaterials medical device company, and the developer of […]
- Alessandro Zeni
- 0 Comments
Tensive publishes positive interim pivotal clinical data showing REGENERA™ supports natural breast reconstruction in Updates in Surgery
Milan, Italy – April 15, 2026 – Tensive S.r.l., a clinical-stage advanced biomaterials medical device company developing REGENERA™ bioresorbable scaffolds […]
- Alessandro Zeni
- 0 Comments
Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy
Milan, Italy – March 04, 2026 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company developing REGENERA™ bioresorbable scaffolds […]
- Alessandro Zeni
- 0 Comments
Tech Tour Growth50 Europe 2026 – Paris – March 17, 2026
Tensive has been selected for the Tech Tour Growth50 Europe 2026 Listing, which recognizes Europe’s top 50 technology companies with […]
- Alessandro Zeni
- 0 Comments
Tensive reports positive pivotal trial top-line results showing REGENERA™ bioresorbable device may transform breast reconstruction
Milan, Italy – January 8, 2026 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company developing REGENERA™/SOFTAG™ bioresorbable scaffolds […]
- Alessandro Zeni
- 0 Comments
J.P. Morgan Healthcare Week – San Francisco – January 12-15, 2026
Tensive will be in San Francisco for meetings with investors, partners and journalists during the JP Morgan Healthcare Conference (week […]
- Alessandro Zeni
- 0 Comments
Tensive publishes positive long-term clinical follow-up data in Breast Cancer on REGENERA™ / SOFTAG™ breast implant
Press release in italian Milan, Italy – 9 October, 2025 Tensive S.r.l, a clinical-stage advanced biomaterials medical device company developing […]
- officine
- 0 Comments
Tensive provides positive clinical updates highlighting potential of REGENERA™ / SOFTAG™ device to transform post-cancer breast reconstruction
Press release in italian Clinical data from two ongoing trials in patients undergoing lumpectomy confirm strong safety profile and growing […]